Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 5/20 | 0.62 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.62 |
| ▸ | FFAR2 | O15552 | 7/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 3/20 | 0.33 |
| ▸ | MMP3 | P08254 | 3/20 | 0.33 |
| ▸ | MMP7 | P09237 | 3/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4943016 | 0.91 | OXTR (0.60) | OXTRAVPR1AFFAR2LMNAPKM | |
| SCHEMBL4942152 | 0.87 | OXTR (0.69) | OXTRAVPR1AFFAR2LMNAPKM | |
| SCHEMBL7085939 | 0.84 | AVPR1A (0.61) | OXTRAVPR1AFFAR2AVPR2HTR1D | |
| SCHEMBL4949415 | 0.84 | AVPR1A (0.61) | OXTRAVPR1AFFAR2AVPR2HTR1D | |
| SCHEMBL7219648 | 0.83 | OXTR (0.75) | OXTRAVPR1AFFAR2AVPR2MMP1 | |
| SCHEMBL4943349 | 0.83 | OXTR (0.75) | OXTRAVPR1AFFAR2AVPR2MMP1 | |
| SCHEMBL31156096 | 0.81 | OXTR (0.85) | OXTRAVPR1AFFAR2LMNAPKM | |
| SCHEMBL31156302 | 0.81 | OXTR (0.85) | OXTRAVPR1AFFAR2LMNAPKM | |
| SCHEMBL4945483 | 0.81 | AVPR1A (0.75) | OXTRAVPR1AFFAR2LMNAPKM | |
| SCHEMBL7086121 | 0.80 | AVPR1A (0.81) | OXTRAVPR1AFFAR2AVPR2HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7018988-B2 | Pharmaceutically active pyrrolidine derivatives as Bax inhibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-03-28 | — | — | US | disclosed |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | MERCK SERONO SA (CH) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | SUCNR1, PYCR1, GLS | OXTR 189/4885AVPR1A 1456/4885FFAR2 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.